These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

325 related articles for article (PubMed ID: 31603849)

  • 1. [Advances in the treatment of Duchenne muscular dystrophy].
    Ortez C; Natera de Benito D; Carrera García L; Expósito J; Nolasco G; Nascimento A
    Medicina (B Aires); 2019; 79 Suppl 3():77-81. PubMed ID: 31603849
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Therapeutic Applications of CRISPR/Cas for Duchenne Muscular Dystrophy.
    Wong TWY; Cohn RD
    Curr Gene Ther; 2017; 17(4):301-308. PubMed ID: 29173172
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Live-imaging of revertant and therapeutically restored dystrophin in the Dmd
    Petkova MV; Stantzou A; Morin A; Petrova O; Morales-Gonzalez S; Seifert F; Bellec-Dyevre J; Manoliu T; Goyenvalle A; Garcia L; Richard I; Laplace-Builhé C; Schuelke M; Amthor H
    Neuropathol Appl Neurobiol; 2020 Oct; 46(6):602-614. PubMed ID: 32573804
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Mdx mice inducibly expressing dystrophin provide insights into the potential of gene therapy for duchenne muscular dystrophy.
    Ahmad A; Brinson M; Hodges BL; Chamberlain JS; Amalfitano A
    Hum Mol Genet; 2000 Oct; 9(17):2507-15. PubMed ID: 11030755
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Prevention of muscular dystrophy in mice by CRISPR/Cas9-mediated editing of germline DNA.
    Long C; McAnally JR; Shelton JM; Mireault AA; Bassel-Duby R; Olson EN
    Science; 2014 Sep; 345(6201):1184-1188. PubMed ID: 25123483
    [TBL] [Abstract][Full Text] [Related]  

  • 6. CRISPR Correction of Duchenne Muscular Dystrophy.
    Min YL; Bassel-Duby R; Olson EN
    Annu Rev Med; 2019 Jan; 70():239-255. PubMed ID: 30379597
    [TBL] [Abstract][Full Text] [Related]  

  • 7. CRISPR technologies for the treatment of Duchenne muscular dystrophy.
    Choi E; Koo T
    Mol Ther; 2021 Nov; 29(11):3179-3191. PubMed ID: 33823301
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Advances in genetic therapeutic strategies for Duchenne muscular dystrophy.
    Guiraud S; Chen H; Burns DT; Davies KE
    Exp Physiol; 2015 Dec; 100(12):1458-67. PubMed ID: 26140505
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Exon Snipping in Duchenne Muscular Dystrophy.
    Kemaladewi DU; Cohn RD
    Trends Mol Med; 2016 Mar; 22(3):187-189. PubMed ID: 26856237
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Targeted exon skipping as a potential gene correction therapy for Duchenne muscular dystrophy.
    Aartsma-Rus A; Bremmer-Bout M; Janson AA; den Dunnen JT; van Ommen GJ; van Deutekom JC
    Neuromuscul Disord; 2002 Oct; 12 Suppl 1():S71-7. PubMed ID: 12206800
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Duchenne muscular dystrophy: an updated review of common available therapies.
    Salmaninejad A; Valilou SF; Bayat H; Ebadi N; Daraei A; Yousefi M; Nesaei A; Mojarrad M
    Int J Neurosci; 2018 Sep; 128(9):854-864. PubMed ID: 29351004
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Alterations in Notch signalling in skeletal muscles from mdx and dko dystrophic mice and patients with Duchenne muscular dystrophy.
    Church JE; Trieu J; Chee A; Naim T; Gehrig SM; Lamon S; Angelini C; Russell AP; Lynch GS
    Exp Physiol; 2014 Apr; 99(4):675-87. PubMed ID: 24443351
    [TBL] [Abstract][Full Text] [Related]  

  • 13. New developments in the use of gene therapy to treat Duchenne muscular dystrophy.
    Jarmin S; Kymalainen H; Popplewell L; Dickson G
    Expert Opin Biol Ther; 2014 Feb; 14(2):209-30. PubMed ID: 24308293
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Differential effects of dystrophin and utrophin gene transfer in immunocompetent muscular dystrophy (mdx) mice.
    Ebihara S; Guibinga GH; Gilbert R; Nalbantoglu J; Massie B; Karpati G; Petrof BJ
    Physiol Genomics; 2000 Sep; 3(3):133-44. PubMed ID: 11015608
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The AAV-mediated and RNA-guided CRISPR/Cas9 system for gene therapy of DMD and BMD.
    Wang JZ; Wu P; Shi ZM; Xu YL; Liu ZJ
    Brain Dev; 2017 Aug; 39(7):547-556. PubMed ID: 28390761
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Development of CRISPR-Mediated Systems in the Study of Duchenne Muscular Dystrophy.
    Cai A; Kong X
    Hum Gene Ther Methods; 2019 Jun; 30(3):71-80. PubMed ID: 31062609
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Nonsense readthrough therapy for Duchenne muscular dystrophy].
    Takeshima Y
    Rinsho Shinkeigaku; 2014; 54(12):1074-6. PubMed ID: 25672712
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Research progress on disease models and gene therapy of Duchenne muscular dystrophy].
    Li T; Liang P
    Zhejiang Da Xue Xue Bao Yi Xue Ban; 2016 May; 45(6):648-654. PubMed ID: 28247611
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Exon Skipping Therapy Using Phosphorodiamidate Morpholino Oligomers in the mdx52 Mouse Model of Duchenne Muscular Dystrophy.
    Miyatake S; Mizobe Y; Takizawa H; Hara Y; Yokota T; Takeda S; Aoki Y
    Methods Mol Biol; 2018; 1687():123-141. PubMed ID: 29067660
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The Use of Antisense Oligonucleotides for the Treatment of Duchenne Muscular Dystrophy.
    Relizani K; Goyenvalle A
    Methods Mol Biol; 2018; 1687():171-183. PubMed ID: 29067663
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.